Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.64 USD
Change Today -0.0399 / -5.87%
Volume 129.8K
CLRX On Other Exchanges
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

collabrx inc (CLRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/19/15 - $2.74
52 Week Low
08/14/15 - $0.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COLLABRX INC (CLRX)

Related News

No related news articles were found.

collabrx inc (CLRX) Related Businessweek News

No Related Businessweek News Found

collabrx inc (CLRX) Details

CollabRx, Inc. provides cloud-based expert systems to inform healthcare decision-making in the United States and internationally. The company develops and markets medical information and clinical decision support products and services. It offers Genetic Variant Annotation Service, which provides the clinical interpretation of genetic variants in human tumor biopsies; Therapy Finders, a series of cancer-specific Web-based apps that are accessed by physicians and patients; and CancerRx, a mobile app with reference tools, social media, and expert systems. The company’s cloud-based expert systems provide clinical knowledge to institutions, physicians, researchers, and patients for genomics-based medicine in cancer. The company was formerly known as Tegal Corporation and changed its name to CollabRx, Inc. in September 2012. CollabRx, Inc. was founded in 1972 and is headquartered in San Francisco, California.

13 Employees
Last Reported Date: 07/17/15
Founded in 1972

collabrx inc (CLRX) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $293.6K
Chair of The Editorial Advisory Board, Editor...
Total Annual Compensation: $150.0K
Chief Operating Officer and Vice President
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2015.

collabrx inc (CLRX) Key Developments

CollabRx Announces Receipt Of NASDAQ Notice Of Noncompliance For Bid Price

CollabRx, Inc. announced that it received a letter from The NASDAQ Stock Market LLC ("Nasdaq") stating that the bid price of the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule 5550(a)(2). The Nasdaq notification letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted on The Nasdaq Capital Market under the symbol "CLRX." CollabRx has been provided a grace period of 180-calendar days, or until November 30, 2015, to regain compliance with the minimum bid price requirement. If at any time during the 180-day grace period, the minimum closing bid price per share of the Company's common stock closes at or above $1.00 for a minimum of ten consecutive business days (the Nasdaq Staff has the discretion to monitor the stock price for up to 20 trading days), CLRX will regain compliance and the matter will be closed. In the event the Company does not regain compliance within this grace period, it may be eligible to receive an additional 180-day grace period, provided that CLRX meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and provides written notice of its intention to cure the minimum bid price deficiency during the second 180-day grace period by effecting a reverse stock split, if necessary. In the event the Company is not able to regain compliance by the end of the applicable grace period, the Company's securities would be subject to delisting unless the Company requested a hearing before the Nasdaq Listing Qualifications Panel. CollabRx management intends to monitor the stock price and is considering available actions that could be taken to regain compliance if the stock price remains below the $1.00 per share requirement at the end of the applicable grace period.

Medytox Solutions, Inc. and CollabRx, Inc. Announces Executive Changes

Medytox Solutions, Inc. and CollabRx, Inc. announced that they have entered into a definitive merger agreement. Closing of the merger is subject to, among other things, gaining stockholder approvals from both companies, receipt of regulatory approvals and other customary closing conditions. Following the merger, Seamus Lagan will be CEO of the combined company. Thomas Mika and Dr. Paul Billings will be appointed to the combined company’s seven-member board, which will include the five current directors of Medytox. Mr. Mika will serve as Executive Chairman, as well as CEO of CollabRx, Inc., which will operate as a wholly-owned subsidiary of the combined companies.

CollabRx, Inc. Promotes Smruti J. Vidwans to Chief Science Officer

CollabRx, Inc. announced that Smruti J. Vidwans, PhD, currently the company's chief scientist, has been appointed chief science officer. Prior to joining CollabRx, Vidwans was at McKinsey and company where she worked on a developing a range of business and scientific solutions for the pharmaceutical industry.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRX:US $0.64 USD -0.0399

CLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.2x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLLABRX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at